Editorial: Implications for BACE1 Inhibitor Clinical Trials: Adult Conditional BACE1 Knockout Mice Exhibit Axonal...

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• BACE1 (Beta-secretase 1) is crucial for amyloid-beta peptide production, a hallmark of Alzheimer's disease (AD).
• BACE1 inhibitors are under investigation for AD treatment, but their long-term safety and efficacy remain unclear.
• Germline Bace1 knockout in mice causes developmental neurological issues, raising concerns about BACE1 inhibition toxicity.

Purpose of the Study:

• To investigate the effects of BACE1 inhibition specifically in adult organisms.
• To differentiate between developmental and adult-onset consequences of BACE1 deficiency.
• To assess the safety and potential side effects of BACE1 inhibitors in the context of Alzheimer's disease therapy.

Main Methods:

• Generation of tamoxifen-inducible conditional BACE1 knockout mice.
• Induction of Bace1 gene deletion in the whole body of adult mice.
• Phenotypic analysis of adult conditional BACE1 knockout mice, including neuroanatomical and molecular assessments.

Main Results:

• Adult conditional BACE1 knockout mice exhibited largely normal phenotypes, indicating BACE1 is not essential for adult physiological functions.
• A specific phenotype was observed: reduced length and disorganization of the hippocampal mossy fiber infrapyramidal bundle.
• This abnormality correlated with impaired proteolytic processing of CHL1, a neural cell adhesion molecule involved in axonal guidance.

Conclusions:

• BACE1 inhibition in adult mice does not replicate the severe phenotypes seen in developmental BACE1 deficiency.
• However, adult BACE1 knockout suggests potential disruption of hippocampal axonal pathways by BACE1 inhibitors.
• These findings have significant implications for the clinical trial safety and efficacy of BACE1 inhibitor drugs for Alzheimer's disease.